In this episode, I share my review of the hot topics from the AAO 2022 annual meeting and share my thoughts on the new data shared about drug trials and treatments.

Brought to you by Alcon

• Welcome to another exciting episode of Eye Care insider :53
• My review of the hot topics from the AAO 2022 annual meeting 2:20
• Hot Topic #1 – wet AMD treatments 2:40
• Hot Topic #2 – high-dose Eylea 6:20
• Hot Topic #3 – geographic atrophy treatments 10:24
• Thanks for listening 16:04

We’d love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.